Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux with IPC for VTE prevention in abdominal surgery
NCT00038961Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2001
- Primary completion
- Oct 2004
- Modality
- Allosteric Modulators
01
Overview
Phase 3, randomised, double-blind trial in venous thromboembolism (VTE) comparing Fondaparinux + IPC with Placebo + IPC (2 arms). Primary endpoints: venous thromboembolism at Day 10 and major bleeding at Day 32. Started Nov 2001; status: completed.
02
Drugs
fondaparinux
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00038961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038961.